MX368106B - Formulaciones liquidas de st-246 y metodos. - Google Patents

Formulaciones liquidas de st-246 y metodos.

Info

Publication number
MX368106B
MX368106B MX2017006160A MX2017006160A MX368106B MX 368106 B MX368106 B MX 368106B MX 2017006160 A MX2017006160 A MX 2017006160A MX 2017006160 A MX2017006160 A MX 2017006160A MX 368106 B MX368106 B MX 368106B
Authority
MX
Mexico
Prior art keywords
methods
liquid formulations
formulation
novel
cyclodextrins
Prior art date
Application number
MX2017006160A
Other languages
English (en)
Inventor
Dennis E Hruby
A C L Stone Melialani
C Weimers William
R Tyavanagimatt Shanthakumar
Krishna Kasi Gopi
N K Samuel Peter
C Bolken Tove'
Original Assignee
Siga Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Tech Inc filed Critical Siga Tech Inc
Publication of MX368106B publication Critical patent/MX368106B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención proporciona una nueva formulación líquida para solubilizar ST-246 pobremente soluble en ciclodextrinas y un nuevo proceso de preparación de la formulación.
MX2017006160A 2010-08-05 2011-08-02 Formulaciones liquidas de st-246 y metodos. MX368106B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37097110P 2010-08-05 2010-08-05
US201161450359P 2011-03-08 2011-03-08
PCT/US2011/046260 WO2012018810A1 (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods

Publications (1)

Publication Number Publication Date
MX368106B true MX368106B (es) 2019-09-19

Family

ID=45559790

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013001389A MX347795B (es) 2010-08-05 2011-08-02 Formulaciones liquidas de st-246 y metodos.
MX2017006160A MX368106B (es) 2010-08-05 2011-08-02 Formulaciones liquidas de st-246 y metodos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013001389A MX347795B (es) 2010-08-05 2011-08-02 Formulaciones liquidas de st-246 y metodos.

Country Status (15)

Country Link
US (5) US9233097B2 (es)
EP (1) EP2600715B1 (es)
JP (1) JP5898196B2 (es)
KR (1) KR101868117B1 (es)
CN (2) CN106074370A (es)
AR (1) AR082566A1 (es)
AU (1) AU2011285871B8 (es)
BR (1) BR112013002646B1 (es)
CA (1) CA2807528C (es)
DK (1) DK2600715T3 (es)
IL (1) IL224430B (es)
MX (2) MX347795B (es)
SG (3) SG10201506031UA (es)
WO (1) WO2012018810A1 (es)
ZA (1) ZA201300930B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN104414983B (zh) * 2013-08-28 2018-09-04 山东新时代药业有限公司 一种注射用福沙匹坦二甲葡胺无菌冻干粉末及其制备工艺
AU2014353235B2 (en) * 2013-11-19 2019-05-09 Siga Technologies, Inc. Rehydration of micronized tecovirimat monohydrate
WO2015191931A1 (en) * 2014-06-12 2015-12-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
WO2016162673A1 (en) 2015-04-10 2016-10-13 Bae Systems Plc Long range sensor apparatus and method of providing a long range sensor apparatus
CN107625967B (zh) 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
CN107638571B (zh) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞口服药物组合物及其制备方法
CN106407676A (zh) * 2016-09-12 2017-02-15 广东省农业科学院动物科学研究所 一种基于蒙特卡罗模拟的抗菌药物药效计算方法
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US20230082992A1 (en) * 2021-09-11 2023-03-16 Viron Therapeutics LLC Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
CN116211821A (zh) * 2023-02-06 2023-06-06 青岛增益安生物科技有限公司 一种特考韦瑞的药物混合方式
US11903962B1 (en) 2023-05-07 2024-02-20 Michael Farber Isoxazoline complexes and compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080080A1 (en) 2002-03-21 2003-10-02 Regents Of The University Of Minnesota Cyclodextrin compositions and methods of treating viral infections
JP4884216B2 (ja) * 2003-06-20 2012-02-29 シガ テクノロジーズ，インコーポレーテッド オルトポックスウイルス感染及び関連疾患を治療及び予防するための化合物、組成物及び方法
JP2008525418A (ja) * 2004-12-23 2008-07-17 ファイザー・リミテッド ケモカインｃｃｒ５受容体に対して活性を有する８−アザ−ビシクロ（３．２．１）オクタン誘導体
US8642577B2 (en) * 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
EP2952197B1 (en) 2005-10-26 2017-04-26 CyDex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
ES2359856T3 (es) 2006-11-21 2011-05-27 Novartis Ag Formulación parenteral estable que contiene un inhibidor de vsr de una estructura de benzodiazepina.
MX348481B (es) 2007-04-23 2017-06-15 Siga Tech Inc Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
US8242106B2 (en) 2008-08-01 2012-08-14 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use

Also Published As

Publication number Publication date
US10124071B2 (en) 2018-11-13
EP2600715B1 (en) 2019-12-11
US10864282B2 (en) 2020-12-15
KR101868117B1 (ko) 2018-06-18
US20180185514A1 (en) 2018-07-05
CA2807528C (en) 2018-09-25
BR112013002646B1 (pt) 2022-01-04
BR112013002646A2 (es) 2013-02-04
CA2807528A1 (en) 2012-02-09
US20190038767A1 (en) 2019-02-07
SG187243A1 (en) 2013-02-28
AU2011285871B8 (en) 2015-05-14
ZA201300930B (en) 2015-11-25
AU2011285871B2 (en) 2015-04-23
AU2011285871A1 (en) 2013-02-21
JP5898196B2 (ja) 2016-04-13
US20140011854A1 (en) 2014-01-09
EP2600715A1 (en) 2013-06-12
IL224430B (en) 2019-09-26
WO2012018810A1 (en) 2012-02-09
US10576165B2 (en) 2020-03-03
EP2600715A4 (en) 2016-04-20
US9233097B2 (en) 2016-01-12
US20160082128A1 (en) 2016-03-24
JP2013532729A (ja) 2013-08-19
WO2012018810A9 (en) 2012-04-05
MX2013001389A (es) 2013-06-07
DK2600715T3 (da) 2020-03-16
SG10202105262QA (en) 2021-06-29
CN106074370A (zh) 2016-11-09
MX347795B (es) 2017-05-12
US9907859B2 (en) 2018-03-06
KR20130135836A (ko) 2013-12-11
AU2011285871A8 (en) 2015-05-14
AR082566A1 (es) 2012-12-19
CN103281898A (zh) 2013-09-04
SG10201506031UA (en) 2015-09-29
US20200138974A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
MX368106B (es) Formulaciones liquidas de st-246 y metodos.
PH12014502797A1 (en) Immunoconjugates comprising anti-cd22 antibodies
PH12014502827A1 (en) Immunoconjugates comprising anti-cd79b antibodies
PH12018500046A1 (en) Anti-mesothelin antibodies and immunoconjugates
MY165002A (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
PH12014502826A1 (en) Immunoconjugates comprising anti-cd79b antibodies
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12013502230A1 (en) Multispecific antibodies
BR112012015721A2 (pt) modificação covalente de proteínas dirigida por ligante
PH12014502825A1 (en) Immunoconjugates comprising anti-cd22 antibodies
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MX2014004022A (es) Anticuerpos anti-htra1 y metodos de uso.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
JO3755B1 (ar) تركيبات تستوستيرون
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
MX343035B (es) Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.
UA111475C2 (uk) Способи лікування із застосуванням ліпідних сполук
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
MX2013004693A (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF